Education
About Us
Working with TipRanks
Follow Us
GRI Bio (GRI)
NASDAQ:GRI
GRI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.10 - $130.61
Previous CloseN/A
Volume96.89K
Average Volume (3M)595.92K
Market Cap
$880.10K
Enterprise Value-$5.33M
Total Cash (Recent Filing)$1.81M
Total Debt (Recent Filing)$14.00K
Price to Earnings (P/E)―
Beta1.33
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-203.36
Shares Outstanding727,358
10 Day Avg. Volume1,747,708
30 Day Avg. Volume595,921
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap-6.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.25
Enterprise Value/Ebitda0.65
Forecast
1Y Price Target
$10.00Price Target Upside651.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Ownership Overview
6.41%
Insiders
0.13% Mutual Funds
0.34% Other Institutional Investors
93.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GRI FAQ
What was GRI Bio’s price range in the past 12 months?
GRI Bio lowest stock price was $1.10 and its highest was $130.61 in the past 12 months.
What is GRI Bio’s market cap?
GRI Bio’s market cap is $880.10K.
When is GRI Bio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were GRI Bio’s earnings last quarter?
Currently, no data Available
Is GRI Bio overvalued?
According to Wall Street analysts GRI Bio’s price is currently Undervalued.
Does GRI Bio pay dividends?
GRI Bio does not currently pay dividends.
What is GRI Bio’s EPS estimate?
GRI Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GRI Bio have?
GRI Bio has 727,358 shares outstanding.
What happened to GRI Bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of GRI Bio?
Currently, no hedge funds are holding shares in GRI
---
Company Description
GRI Bio
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
---
GRI Stock 12 Month Forecast
Average Price Target
$10.00
▲(651.88% Upside)
Technical Analysis
Best Analysts Covering GRI
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-84.25%
reiterated a buy rating 4 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -84.25% per trade.
---